Search company, investor...

Avalon Pharmaceuticals

Founded Year



Acquired | Acquired

Total Raised




About Avalon Pharmaceuticals

Avalon Pharmaceuticals utilizes the AvalonRx Drug Discovery Engine which uses RNAi gene disruption signatures for the isolation of drugs against previously "intractable" targets. The Engine monitors changes in gene expression which in turn aims to provide a strongly predictive foundation for identifying better medicines. Per the company, Avalon's oncology pipeline currently has multiple products with mechanisms of action and also against targets previously considered "intractable".

Headquarters Location

20358 Seneca Meadows Parkway

Germantown, Maryland, 20876,

United States


Missing: Avalon Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Avalon Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Avalon Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Avalon Pharmaceuticals is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Latest Avalon Pharmaceuticals News

Clinical Data Completes Acquisition of Avalon Pharmaceuticals

Jun 16, 2017

May 28, 2009 04:06 PM Eastern Daylight Time NEWTON, Mass.--( BUSINESS WIRE )--Clinical Data, Inc. (Nasdaq: CLDA) today announced the completion of its acquisition of Avalon Pharmaceuticals, Inc. Clinical Data acquired Avalon through an all-stock transaction valued at approximately $10 million, based upon the 15-day volume weighted average price of $12.49 for Clinical Data’s common stock through Monday, October 27, 2008, the date of the definitive merger agreement. As a result of the acquisition, the common stock of Avalon ceased trading at market close on May 28, 2009. As part of the acquisition, former Avalon stockholders will receive 0.0470 of a share of Clinical Data common stock and a contingent value right (CVR) in exchange for each share of Avalon common stock held by them. Each CVR represents the right to receive up to an additional 0.01175 shares of Clinical Data common stock based on payments received by Avalon or its affiliates (including Clinical Data) under certain Avalon contracts. As a consequence of the receipt of a recent termination payment from Merck under these contracts, each CVR represents the right to receive at least 0.00940 of a share of Clinical Data common stock, payable after June 30, 2010. About Clinical Data, Inc. Clinical Data is a global biotechnology company unlocking the potential of genomic discovery, From Targeted Science to Better Healthcare®. The Company is utilizing its biomarker expertise and intellectual property to develop and commercialize targeted therapeutics, as well as genetic and pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy, thereby improving health while reducing costs. Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, healthcare professionals and payors worldwide. To learn more, please visit the Company's website at .

Avalon Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Avalon Pharmaceuticals founded?

    Avalon Pharmaceuticals was founded in 1999.

  • Where is Avalon Pharmaceuticals's headquarters?

    Avalon Pharmaceuticals's headquarters is located at 20358 Seneca Meadows Parkway, Germantown.

  • What is Avalon Pharmaceuticals's latest funding round?

    Avalon Pharmaceuticals's latest funding round is Acquired.

  • How much did Avalon Pharmaceuticals raise?

    Avalon Pharmaceuticals raised a total of $122.02M.

  • Who are the investors of Avalon Pharmaceuticals?

    Investors of Avalon Pharmaceuticals include Clinical Data, BVF Partners, Passport Management, Federated Investors, Federated Equity Funds - Federated Kaufmann Fund and 35 more.

  • Who are Avalon Pharmaceuticals's competitors?

    Competitors of Avalon Pharmaceuticals include LifeSensors, Melinta Therapeutics, BrightPath Biotherapeutics, Cellzome, LifeGen Technologies and 11 more.

Compare Avalon Pharmaceuticals to Competitors

Sekmed S.R.L.

Sekmed is a biotechnology company working in the drug discovery and gene hunting field. The company's fishing nets are the company's DC-based bioassays, and the company are looking for catch: drug candidates to create vaccines, improve transplant acceptance and treat autoimmunity.


TcLand Expression is a provider in the field of gene expression biomarkers in immunology

Proteintech Group Logo
Proteintech Group

Proteintech Group is engaged in the design, development and marketing of antibody and antibody-chips in the bioresearch field.


GNI's "gene network" technology is based on a combination of wet lab work and lots of computing power to figure out how the 30,000-plus protein-making genes in the human genome interact. Its primary product is a drug discovery engine to quickly identify genes for drug development, as well as figure out which genes are affected by a given drug.

CODA Genomics

CODA Genomics aims to take a biology process that normally yields an entire array of unspecific products, and through computer optimization and a step-wise process, directs an assembly of the desired product that is thermodynamically efficient. The company's CODExpress Gene kit aims to allow researchers to express custom proteins in their lab with their own gene constructs and variants.

Iceni Pharmaceuticals

Iceni Pharmaceuticals develops cancer therapies, specializing in repurposing and reformulating existing drugs for new indications. The company was formerly known as BigDNA. Iceni Pharmaceuticals was founded in 2006 and is based in Edinburgh, United Kingdom.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.